New Analyses from Pivotal Phase 3 Trials of Oral Ozanimod to Be Presented at ECTRIMS 2018
Ozanimod showed effects on cognitive processing speed in a post hoc analysis of 12-month data from SUNBEAM™ pivotal trial.
In separate post hoc analysis of pooled data from phase 3 RADIANCE™ Part B and SUNBEAM trials, ozanimod reduced annualized relapse rates and MRI lesions at 12 months in patients with a disease state defined as early relapsing multiple sclerosis compared with patients with more advanced disease.
These products may not be approved and/or licensed in all countries where this website is accessible. For information about Celgene products and services in countries other than the U.S., please contact the local office (as listed under the Global Network).